Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 646 to 660 of 1688 results for carers

  1. Acalabrutinib with venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia ID6232

    Awaiting development [GID-TA11230] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Tolebrutinib for treating relapsing multiple sclerosis ID6351

    Awaiting development [GID-TA11333] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A ID6312

    Awaiting development [GID-TA11329] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Effective record keeping and ordering of medicines

    A quick guide for home care managers providing medicines support

    Social care quick guide
    Published
    25 May 2022

  5. Masitinib with riluzole for treating amyotrophic lateral sclerosis TS ID 10728

    Awaiting development [GID-TA11071] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Spesolimab for treating generalised pustular psoriasis flares [ID3963]

    In development [GID-TA10871] Expected publication date: 19 March 2025

    Technology appraisal guidance
    In development

  7. Technology appraisal submission templates and supporting documents

    confidential information (Word) Other stakeholder templates Patient carer organisation (Word) Professional organisation (Word)...

  8. Nipocalimab for treating generalised myasthenia gravis TS ID 11958

    Awaiting development [GID-TA11492] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Opicapone for adjunctive treatment of motor signs and symptoms in Parkinson's disease TS ID 11941

    Awaiting development [GID-TA11481] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Lurbinectedin with atezolizumab for maintenance treatment of extensive-stage small-cell lung cancer TS ID 11970

    Awaiting development [GID-TA11502] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Subcutaneous efgartigmod with recombinant human hyaluronidase PH20 for treating primary immune thrombocytopenia TS ID 11977

    Awaiting development [GID-TA11507] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. MIM8 for preventing bleeding episodes in haemophilia A in people 1 year and over ID6400

    Awaiting development [GID-TA11509] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular or marginal zone lymphoma after 1 or more anti-CD20 treatments ID6413

    Awaiting development [GID-TA11488] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Pembrolizumab with olaparib and chemoradiation for previously untreated limited-stage ID6412 small-cell lung cancer TS ID 11975

    Awaiting development [GID-TA11497] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer ID6433

    Awaiting development [GID-TA11489] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development